Helixmith Co., Ltd., formerly known as ViroMed, is a biotechnology company headquartered in Seoul, South Korea. Founded in 1996, Helixmith focuses on developing innovative gene therapy products. The company's flagship product, Engensis (VM202), is a non-viral plasmid DNA therapy designed to treat a variety of conditions including diabetic peripheral neuropathy, diabetic foot ulcers, amyotrophic lateral sclerosis (ALS), coronary artery disease, and Charcot-Marie-Tooth disease. Helixmith is also involved in developing CAR-T cell therapy for solid tumors and AAV gene therapy for neuromuscular diseases. The company has a strong research pipeline and operates in both South Korea and the United States.